vs
Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Community Healthcare Trust Inc is the larger business by last-quarter revenue ($30.9M vs $28.1M, roughly 1.1× ARS Pharmaceuticals, Inc.). Community Healthcare Trust Inc runs the higher net margin — 46.6% vs -147.1%, a 193.8% gap on every dollar of revenue. On growth, Community Healthcare Trust Inc posted the faster year-over-year revenue change (5.6% vs -67.6%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CHCT vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.9M | $28.1M |
| Net Profit | $14.4M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | — | -147.6% |
| Net Margin | 46.6% | -147.1% |
| Revenue YoY | 5.6% | -67.6% |
| Net Profit YoY | 687.6% | -182.8% |
| EPS (diluted) | $0.52 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.9M | $28.1M | ||
| Q3 25 | $31.1M | $32.5M | ||
| Q2 25 | $29.1M | $15.7M | ||
| Q1 25 | $30.1M | $8.0M | ||
| Q4 24 | $29.3M | $86.6M | ||
| Q3 24 | $29.6M | $2.1M | ||
| Q2 24 | $27.5M | $500.0K | ||
| Q1 24 | $29.3M | $0 |
| Q4 25 | $14.4M | $-41.3M | ||
| Q3 25 | $1.6M | $-51.2M | ||
| Q2 25 | $-12.6M | $-44.9M | ||
| Q1 25 | $1.6M | $-33.9M | ||
| Q4 24 | $1.8M | $49.9M | ||
| Q3 24 | $1.7M | $-19.1M | ||
| Q2 24 | $-10.4M | $-12.5M | ||
| Q1 24 | $3.7M | $-10.3M |
| Q4 25 | — | -147.6% | ||
| Q3 25 | — | -163.7% | ||
| Q2 25 | — | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% | ||
| Q1 24 | — | — |
| Q4 25 | 46.6% | -147.1% | ||
| Q3 25 | 5.3% | -157.4% | ||
| Q2 25 | -43.2% | -285.6% | ||
| Q1 25 | 5.3% | -425.7% | ||
| Q4 24 | 6.3% | 57.7% | ||
| Q3 24 | 5.9% | -925.0% | ||
| Q2 24 | -37.9% | -2503.2% | ||
| Q1 24 | 12.5% | — |
| Q4 25 | $0.52 | $-0.41 | ||
| Q3 25 | $0.03 | $-0.52 | ||
| Q2 25 | $-0.50 | $-0.46 | ||
| Q1 25 | $0.03 | $-0.35 | ||
| Q4 24 | $0.04 | $0.52 | ||
| Q3 24 | $0.04 | $-0.20 | ||
| Q2 24 | $-0.42 | $-0.13 | ||
| Q1 24 | $0.11 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.3M | $245.0M |
| Total DebtLower is stronger | $532.2M | $96.4M |
| Stockholders' EquityBook value | $429.4M | $114.3M |
| Total Assets | $990.8M | $327.7M |
| Debt / EquityLower = less leverage | 1.24× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3M | $245.0M | ||
| Q3 25 | $3.4M | $288.2M | ||
| Q2 25 | $4.9M | $240.1M | ||
| Q1 25 | $2.3M | $275.7M | ||
| Q4 24 | $4.4M | $314.0M | ||
| Q3 24 | $2.8M | $204.6M | ||
| Q2 24 | $734.0K | $218.7M | ||
| Q1 24 | $3.8M | $223.6M |
| Q4 25 | $532.2M | $96.4M | ||
| Q3 25 | $530.1M | $96.2M | ||
| Q2 25 | $500.1M | — | ||
| Q1 25 | $496.0M | — | ||
| Q4 24 | $486.0M | $0 | ||
| Q3 24 | $473.7M | — | ||
| Q2 24 | $457.6M | — | ||
| Q1 24 | $442.3M | — |
| Q4 25 | $429.4M | $114.3M | ||
| Q3 25 | $426.8M | $147.7M | ||
| Q2 25 | $437.8M | $192.3M | ||
| Q1 25 | $461.3M | $229.0M | ||
| Q4 24 | $476.0M | $256.8M | ||
| Q3 24 | $477.2M | $201.0M | ||
| Q2 24 | $497.8M | $215.2M | ||
| Q1 24 | $511.6M | $223.9M |
| Q4 25 | $990.8M | $327.7M | ||
| Q3 25 | $987.3M | $372.8M | ||
| Q2 25 | $966.3M | $313.5M | ||
| Q1 25 | $985.1M | $327.3M | ||
| Q4 24 | $992.6M | $351.2M | ||
| Q3 24 | $981.8M | $217.6M | ||
| Q2 24 | $983.2M | $222.0M | ||
| Q1 24 | $982.7M | $227.6M |
| Q4 25 | 1.24× | 0.84× | ||
| Q3 25 | 1.24× | 0.65× | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.02× | 0.00× | ||
| Q3 24 | 0.99× | — | ||
| Q2 24 | 0.92× | — | ||
| Q1 24 | 0.86× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $56.4M | $-43.5M |
| Free Cash FlowOCF − Capex | $35.9M | — |
| FCF MarginFCF / Revenue | 116.0% | — |
| Capex IntensityCapex / Revenue | 66.3% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.91× | — |
| TTM Free Cash FlowTrailing 4 quarters | $62.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $56.4M | $-43.5M | ||
| Q3 25 | $12.7M | $-47.0M | ||
| Q2 25 | $13.8M | $-39.6M | ||
| Q1 25 | $14.4M | $-40.7M | ||
| Q4 24 | $58.9M | $42.0M | ||
| Q3 24 | $13.8M | $-14.5M | ||
| Q2 24 | $16.7M | $-7.3M | ||
| Q1 24 | $12.6M | $-6.7M |
| Q4 25 | $35.9M | — | ||
| Q3 25 | $7.6M | $-47.2M | ||
| Q2 25 | $9.6M | $-39.6M | ||
| Q1 25 | $9.7M | $-40.8M | ||
| Q4 24 | $34.2M | $41.7M | ||
| Q3 24 | $6.7M | $-14.6M | ||
| Q2 24 | $9.5M | $-7.3M | ||
| Q1 24 | $7.5M | $-6.8M |
| Q4 25 | 116.0% | — | ||
| Q3 25 | 24.6% | -145.4% | ||
| Q2 25 | 32.9% | -252.2% | ||
| Q1 25 | 32.3% | -512.1% | ||
| Q4 24 | 116.9% | 48.2% | ||
| Q3 24 | 22.5% | -706.3% | ||
| Q2 24 | 34.7% | -1463.4% | ||
| Q1 24 | 25.7% | — |
| Q4 25 | 66.3% | 0.0% | ||
| Q3 25 | 16.3% | 0.6% | ||
| Q2 25 | 14.5% | 0.3% | ||
| Q1 25 | 15.6% | 1.1% | ||
| Q4 24 | 84.1% | 0.3% | ||
| Q3 24 | 24.2% | 6.8% | ||
| Q2 24 | 26.1% | 7.6% | ||
| Q1 24 | 17.4% | — |
| Q4 25 | 3.91× | — | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | — | ||
| Q4 24 | 32.14× | 0.84× | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHCT
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
